124 related articles for article (PubMed ID: 33341678)
1. Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma.
Zhong Y; Lin F; Xu F; Schubert J; Wu J; Wainwright L; Zhao X; Cao K; Fan Z; Chen J; Lang SS; Kennedy BC; Viaene AN; Santi M; Resnick AC; Storm PB; Li MM
Cancer Genet; 2021 Apr; 252-253():37-42. PubMed ID: 33341678
[TBL] [Abstract][Full Text] [Related]
2. Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.
Lopez-Nunez O; Surrey LF; Alaggio R; Fritchie KJ; John I
Genes Chromosomes Cancer; 2020 Aug; 59(8):495-499. PubMed ID: 32222087
[TBL] [Abstract][Full Text] [Related]
3. Unusual high-grade and low-grade glioma in an infant with PPP1CB-ALK gene fusion.
Ng A; Levy ML; Malicki DM; Crawford JR
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30709888
[No Abstract] [Full Text] [Related]
4. Targetable molecular alterations in congenital glioblastoma.
Gilani A; Donson A; Davies KD; Whiteway SL; Lake J; DeSisto J; Hoffman L; Foreman NK; Kleinschmidt-DeMasters BK; Green AL
J Neurooncol; 2020 Jan; 146(2):247-252. PubMed ID: 31875306
[TBL] [Abstract][Full Text] [Related]
5. Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?
Olsen TK; Panagopoulos I; Meling TR; Micci F; Gorunova L; Thorsen J; Due-Tønnessen B; Scheie D; Lund-Iversen M; Krossnes B; Saxhaug C; Heim S; Brandal P
Neuro Oncol; 2015 Oct; 17(10):1365-73. PubMed ID: 25795305
[TBL] [Abstract][Full Text] [Related]
6. Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC.
Zito Marino F; Botti G; Aquino G; Ferrero S; Gaudioso G; Palleschi A; Rocco D; Salvi R; Micheli MC; Micheli P; Morabito A; Rocco G; Giordano A; De Cecio R; Franco R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664698
[No Abstract] [Full Text] [Related]
7. A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
Mack SC; Bertrand KC
Clin Cancer Res; 2023 Jul; 29(14):2567-2569. PubMed ID: 37260294
[TBL] [Abstract][Full Text] [Related]
8. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
Li W; Liu Y; Li W; Chen L; Ying J
J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
[TBL] [Abstract][Full Text] [Related]
9. ALK alterations in salivary gland carcinomas.
Majewska H; Gorczyński A; Czapiewski P; Menon R; Mueller J; Lakis S; Heuckmann JM; Laco J; Gupta R; Andreasen S; Stodulski D; Iliszko M; Dziadziuszko R; Jassem J; Heukamp LC; Biernat W
Virchows Arch; 2021 May; 478(5):933-941. PubMed ID: 33237469
[TBL] [Abstract][Full Text] [Related]
10. Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment.
Kunimasa K; Kato K; Imamura F; Kukita Y
PLoS One; 2019; 14(9):e0222233. PubMed ID: 31513617
[TBL] [Abstract][Full Text] [Related]
11. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.
Tong Y; Zhao Z; Liu B; Bao A; Zheng H; Gu J; McGrath M; Xia Y; Tan B; Song C; Li Y
J Exp Clin Cancer Res; 2018 Mar; 37(1):68. PubMed ID: 29587818
[TBL] [Abstract][Full Text] [Related]
12. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
[TBL] [Abstract][Full Text] [Related]
13. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
14. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (
Tang Z; Wang L; Tang G; Medeiros LJ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412611
[TBL] [Abstract][Full Text] [Related]
16. ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.
Liu Y; Wu S; Shi X; Liang Z; Zeng X
J Cancer Res Clin Oncol; 2020 May; 146(5):1307-1320. PubMed ID: 32128622
[TBL] [Abstract][Full Text] [Related]
17. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.
Blandin AF; Giglio R; Graham MS; Garcia G; Malinowski S; Woods JK; Ramkissoon S; Ramkissoon L; Dubois F; Schoolcraft K; Tsai J; Wang D; Jones R; Vogelzang J; Pelton K; Becker S; Watkinson F; Sinai C; Cohen EF; Booker MA; Tolstorukov MY; Haemels V; Goumnerova L; Wright K; Kieran M; Fehnel K; Reardon D; Tauziede-Espariat A; Lulla R; Carcamo B; Chaleff S; Charest A; De Smet F; Ligon AH; Dubuc A; Pages M; Varlet P; Wen PY; Alexander BM; Chi S; Alexandrescu S; Kittler R; Bachoo R; Bandopadhayay P; Beroukhim R; Ligon KL
Clin Cancer Res; 2023 Jul; 29(14):2651-2667. PubMed ID: 36780194
[TBL] [Abstract][Full Text] [Related]
18. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
19. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
[TBL] [Abstract][Full Text] [Related]
20. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A
Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
